06-23-2024  8:25 am   •   PDX and SEA Weather

Albert Bourla, DVM, Ph.D. Chief Executive Officer Pfizer
Ellen F. Rosenblum, State of Oregon Attorney General
Published: 12 March 2019

SALEM, OREGON—Attorney General Rosenblum today announced a $975,000 settlement with the pharmaceutical company, Pfizer, for distributing misleading marketing materials and coupons to Oregon consumers. The coupons distributed by Pfizer were designed to help consumers afford copays or deductibles associated with brand-name drugs. (Read: 'The Skanner Editorial: Consumers Need Transparency in Medication Pricing') 

A large portion of the settlement, $620,000, will go to support two local organizations, Project Access Now and Virginia Garcia Memorial Health Center, which both help uninsured and underinsured Oregonians afford health care. The remaining amount will help the Department of Justice fund future investigations and reimburse consumers who used the misleading coupons.

“When it comes to the price of medications, we will not tolerate pharmaceutical companies taking advantage of Oregonians.

"Pfizer enticed consumers with these coupons for one reason only —to sell its brand-name drugs instead of a cheaper generic. These coupons were simply not a good deal for consumers, who were misled by Pfizer into thinking they were,” said Attorney General Rosenblum. “I am pleased that two wonderful Oregon non-profits who help some of our most vulnerable afford health care will benefit from the settlement.”

After a four-month investigation, the Oregon Department of Justice (DOJ) found that Pfizer distributed misleading marketing materials and coupons that stated that consumers would “pay no more than” a certain amount, such as $15, $20, $25, at the pharmacy for four of Pfizer’s drugs: Flector Patch, Estring, and Quillivant/Quillichew. But, in reality, many consumers had to pay significantly more. Oregon DOJ’s investigation identified 371 Oregon customers who paid over $40,000 in total over the amount promised by the coupon the first time a prescription was filled.

From the settlement, $620,000 will fund two different grants for two Oregon nonprofits. A total of $500,000 will go to Project Access NOW (PANOW), a community health organization that serves low-income uninsured and underinsured Oregonians. The organization works with clinics, health systems and community-based organizations to provide access to care and services for Oregonians. PANOW uses the Providence Pharmacy Benefit Management system to provide very low, or no cost, medications to the uninsured. In addition, they are able to provide co-pay assistance.

An additional $120,000 will go to Virginia Garcia Memorial Health Center, which provides health care to Oregonians, especially migrant and seasonal farmworkers who often face barriers to receiving quality health care. Virginia Garcia offers on-site pharmacies at primary care clinics in Beaverton, Cornelius, Hillsboro, McMinnville and Newberg.

Consumers who used the misleading coupons will be contacted in the mail. The average payment each person will receive is $108.

“This is not the first time we have had to go after Pfizer for violating our laws. But we sure hope it’s the last,” said AG Rosenblum. Since 2003, Oregon has recouped over $10 million in civil settlements from Pfizer, including:

  • In 2003, Oregon led a $4 million multistate investigation into how Pfizer’s misrepresented the effectiveness of Zithromax, an antibiotic to treat ear infections in children. The 19-state settlement ultimately required Pfizer to finance a $2 million public service ad campaign, and pay Oregon $500,000.
  • In 2008, Oregon led a multistate investigation regarding off-label promotion of the prescription drugs Bextra and Celebrex, eventually recovering $4.3 million for Oregon.
  • In 2012, Oregon independently obtained a settlement regarding Pfizer’s marketing claims for the drugs Zyvox and Lyrica, recovering $3.34 million for Oregon.
  • In 2012 Oregon successfully enforced its prior settlements, requiring Pfizer to pay $1 million for its misleading marketing of EpiPen and Zmax.
  • In 2014, Oregon led a multistate investigation resolving Pfizer subsidiary Wyeth’s off-label promotion of the immunosuppressive drug Rapamune. The settlement included $1.2 million for Oregon.

Rosenblum commended the work of Assistant Attorney General David Hart and his investigative team in the Consumer Protection/Financial Fraud Section of the Oregon Department of Justice for their efforts in investigating and resolving this case.

The Oregon Department of Justice (DOJ) is led by Attorney General Ellen Rosenblum, and serves as the state’s law firm. The Oregon DOJ advocates for and protects all Oregonians, especially the most vulnerable, such as children and seniors.

Recently Published by The Skanner News

  • Default
  • Title
  • Date
  • Random